中文摘要：

目的探讨门诊精神分裂症患者服用奥氮平致中心性肥胖的护理干预方法及效果。方法选择2012年1月，2013年2月到上海交通大学医学院附属精神卫生中心就诊的门诊精神分裂症患者76例．随机分为对照组和干预组．每组各38例。对照组采取常规精神科护理，干预组定期随访并增加代谢不良反应防治指导及相关教育。两组分别在治疗1个月时进行治疗依从性的比较，在治疗1、3、6个月时测量两组的腰围身高比（WHtR）以预测代谢不良反应的发生情况。结果治疗1个月后，干预前后组内比较，对照组治疗依从性差异无统计学意义（P=0．650），干预组治疗依从性显著提高（P〈0．001）；干预后两组比较，干预组的治疗依从性显著高于对照组（P〈0．01）。干预组平均WHtR的增加值显著低于对照组，在治疗1、3、6个月时对照组和干预组的WHtR的增加值分别为（0．44±0．13）比（0．42±0．11），（0．46±0．03）比（0．43±0．03），（0．50±0．03）比（0．47±0．04），差异均有高度统计学意义（P〈0．01）。结论加强相关护理干预可有效控制奥氮平治疗引起的中心性肥胖并提高患者服药依从性，对维持患者身体健康及预防精神分裂症的复发有重要意义。

英文摘要：

Objective To explore the methods and effect of nursing intervention on the central obesity side effect of Olanzap- ine in schizophrenia outpatients. Methods 76 schizophrenia outpatients from January 2012 to February 2013 in Shanghai Mental Health Center Affiliated to Shanghai Jiaotong University of School of Medicine were enrolled and randomly divided in- to two groups of control group （n = 38） and treatment group （n = 38）. Those in the control group were treated with routine nursing only, while those in the treatment group were treated with related health education about metabolic side effects be- sides routine care. Drug compliance of two groups were compared after 1 month, WHtR was measured and compared after treatment for the 1, 3 and 6 month to evaluate the metabolic reactions. Results After 1 month intervention, the intra-group comparison showed no significant change of the drug compliance in control group （P = 0.650）, while showed significance in treatment group （P 〈 0.001）; the inter-group comparison was also significantly different between the two groups （P 〈 0.01）. The WHtR in the treatment group was lower than that of the control group, the gain value of WHtR after intervention for the 1, 3 and 6 month were （0.44±0.13） vs （0.42±0.11）, （0.46±0.03） vs （0.43±0.03）, （0.50±0.03） vs （0.47±0.04）, with statistically significant differenees （P 〈 0.01） respectively. Conclusion Rational nursing care is not only beneficial to improve the drug eompiianee but also reduce the risk of developing central obesity in sehizophrenia patients who take Olanzapine, and it has important implications for their mental and physical health.